Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion (clinicaltrials.gov) - Oct 1, 2026 - P=N/A | N=10 | Not yet recruiting | Sponsor: Bristol-Myers Squibb | Initiation date: May 2026 ➔ Oct 2026
Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NTRK • NTRK1 • NTRK2 • NTRK3 • ROS1
|